



U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. <b>2312/2082B</b>		Serial No. <b>10/032,221</b>	
INFORMATION DISCLOSURE STATEMENT				Applicant(s): <b>Kalluri</b>			
				Filing Date: <b>December 21, 2001</b>		Group: <b>1644</b>	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation YES NO
MH	1.	WO 01/51523A	19 July 2001	PCT	<del>C07K</del>	<del>16/00</del>	
<b>OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)</b>							
MH	2.	Maeshima Y, et al.: Two RGD-independent alpha v beta 3 Integrin binding sites on Tumstatin regulate Distinct anti-tumor properties; <i>Journal of Biological Chemistry</i> , American Society of Biological Chemists, Baltimore MD, US. Vol. 275, No. 31, 4 Aug. 2000, Pages 23745-23750, XP002177918, ISSN: 0021-9258.					
	3.	<del>Copy of European Search Report related to EP 02794346.</del>					
EXAMINER     /Maher Haddad/					DATE CONSIDERED     08/17/2006		
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>							
<small>**Copies of references not provided at the time of this submission.</small>							